Search Results
1L FOLFOXIRI plus cetuximab or bevacizumab for RAS wild-type mCRC
DEEPER: FOLFOXIRI + cetuximab or bevacizumab for 1L mCRC
DEEPER: m-FOLFOXIRI and cetuximab versus bevacizumab in mCRC
FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRC
What is the best treatment for RAS wild-type metastatic colorectal cancer?
Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC
FIRE-4: evaluation of 1L efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC
PARADIGM: panitumumab versus bevacizumab in RAS-wt mCRC
Dr. Cremolini on FOLFOXIRI Plus Bevacizumab For Metastatic Colorectal Cancer
ASCO 2013: Cetuximab superior to bevacizumab for advanced colorectal cancer
Dr. Benson on Sequencing Strategies with Cetuximab in CRC
